Literature DB >> 18493765

Acute interstitial nephritis associated with etanercept.

Toshiro Sugimoto1, Mako Yasuda, Masayoshi Sakaguchi, Tetsuro Koyama, Takashi Uzu, Junichi Nishioka, Atsunori Kashiwagi.   

Abstract

We encountered an adult patient with rheumatoid arthritis who developed acute interstitial nephritis associated with an anti-tumor necrosis factor alpha agent, etanercept.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18493765     DOI： 10.1007/s00296-008-0609-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  6 in total

1.  Chronic overdose of leflunomide inducing interstitial nephritis.

Authors:  Ali A Haydar; Nabil Hujairi; Bruce Kirkham; Robert Hangartner; David J A Goldsmith
Journal:  Nephrol Dial Transplant       Date:  2004-05       Impact factor: 5.992

Review 2.  Development of sarcoidosis during etanercept therapy.

Authors:  Marcos A González-López; Ricardo Blanco; M Carmen González-Vela; Héctor Fernández-Llaca; Vicente Rodríguez-Valverde
Journal:  Arthritis Rheum       Date:  2006-10-15

3.  Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

Authors:  Adam Mor; Clifton O Bingham; Clifton Bingham; Laura Barisoni; Eileen Lydon; H Michael Belmont
Journal:  J Rheumatol       Date:  2005-04       Impact factor: 4.666

4.  Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.

Authors:  Michael B Stokes; Kirk Foster; Glen S Markowitz; Farhang Ebrahimi; William Hines; Darren Kaufman; Brooke Moore; Daniel Wolde; Vivette D D'Agati
Journal:  Nephrol Dial Transplant       Date:  2005-04-19       Impact factor: 5.992

5.  Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis.

Authors:  T W R Doulton; B Tucker; J Reardon; N Velasco
Journal:  Clin Nephrol       Date:  2004-09       Impact factor: 0.975

6.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.